CN118215657A - Kif18a抑制剂 - Google Patents
Kif18a抑制剂 Download PDFInfo
- Publication number
- CN118215657A CN118215657A CN202280076424.9A CN202280076424A CN118215657A CN 118215657 A CN118215657 A CN 118215657A CN 202280076424 A CN202280076424 A CN 202280076424A CN 118215657 A CN118215657 A CN 118215657A
- Authority
- CN
- China
- Prior art keywords
- hydrocarbyl
- compound
- mmol
- reaction
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021113998764 | 2021-11-19 | ||
| CN202111399876 | 2021-11-19 | ||
| CN202210225663 | 2022-03-09 | ||
| CN2022102256638 | 2022-03-09 | ||
| CN202210667619 | 2022-06-13 | ||
| CN2022106676192 | 2022-06-13 | ||
| PCT/CN2022/132954 WO2023088441A1 (zh) | 2021-11-19 | 2022-11-18 | Kif18a抑制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118215657A true CN118215657A (zh) | 2024-06-18 |
Family
ID=86396297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280076424.9A Pending CN118215657A (zh) | 2021-11-19 | 2022-11-18 | Kif18a抑制剂 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4434979A4 (https=) |
| JP (1) | JP2024542199A (https=) |
| KR (1) | KR20240108489A (https=) |
| CN (1) | CN118215657A (https=) |
| AU (1) | AU2022389558A1 (https=) |
| CA (1) | CA3237625A1 (https=) |
| MX (1) | MX2024005996A (https=) |
| WO (1) | WO2023088441A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI844602B (zh) | 2018-12-20 | 2024-06-11 | 美商安進公司 | Kif18a抑制劑 |
| CN119241504A (zh) | 2021-08-26 | 2025-01-03 | 沃拉斯查疗法公司 | Kif18a的螺吲哚啉抑制剂 |
| WO2024022508A1 (zh) * | 2022-07-29 | 2024-02-01 | 武汉人福创新药物研发中心有限公司 | Kif18a抑制剂及用途 |
| TW202416973A (zh) | 2022-08-18 | 2024-05-01 | 美商雅客森醫療公司 | Ｋｉｆ１８ａ抑制劑及其用途 |
| CN117917405A (zh) * | 2022-10-21 | 2024-04-23 | 杭州邦顺制药有限公司 | Kif18a蛋白抑制剂 |
| CN120202002A (zh) * | 2022-11-30 | 2025-06-24 | 微境生物医药科技(上海)有限公司 | 一种用于癌症治疗的药物组合物 |
| EP4628486A1 (en) * | 2022-12-02 | 2025-10-08 | Shenzhen Zhongge Biological Technology Co., Ltd. | Amide or urea compound |
| WO2024146593A1 (zh) * | 2023-01-05 | 2024-07-11 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和医药上的用途 |
| WO2024244972A1 (zh) * | 2023-05-30 | 2024-12-05 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和用途 |
| CN121532380A (zh) * | 2023-07-21 | 2026-02-13 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和用途 |
| WO2025026392A1 (zh) * | 2023-08-02 | 2025-02-06 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
| WO2025036479A1 (zh) * | 2023-08-16 | 2025-02-20 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
| WO2025190888A1 (en) * | 2024-03-12 | 2025-09-18 | F. Hoffmann-La Roche Ag | Macrocyclic kif18a inhibitors and their use thereof |
| TW202547479A (zh) * | 2024-03-27 | 2025-12-16 | 大陸商上海齊魯製藥研究中心有限公司 | 驅動蛋白kif18a抑制劑及其使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO395396A0 (en) * | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| WO2020132651A1 (en) * | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| EP3898616B1 (en) * | 2018-12-20 | 2024-10-02 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| TWI844602B (zh) | 2018-12-20 | 2024-06-11 | 美商安進公司 | Kif18a抑制劑 |
| JP7676308B2 (ja) * | 2018-12-20 | 2025-05-14 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド |
| US12540129B2 (en) * | 2019-08-02 | 2026-02-03 | Amgen Inc. | KIF18A inhibitors |
| AU2020326627B2 (en) * | 2019-08-02 | 2026-01-29 | Amgen Inc. | KIF18A inhibitors |
| WO2021026099A1 (en) * | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| JP2023521802A (ja) * | 2020-04-14 | 2023-05-25 | アムジエン・インコーポレーテツド | 新生物疾患の処置のためのｋｉｆ１８ａ阻害剤 |
| JP2024534572A (ja) * | 2021-09-24 | 2024-09-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ナトリウムチャンネル活性化剤としてのピリジニルアセトアミド誘導体 |
-
2022
- 2022-11-18 AU AU2022389558A patent/AU2022389558A1/en active Pending
- 2022-11-18 JP JP2024529504A patent/JP2024542199A/ja active Pending
- 2022-11-18 EP EP22894970.7A patent/EP4434979A4/en active Pending
- 2022-11-18 CA CA3237625A patent/CA3237625A1/en active Pending
- 2022-11-18 KR KR1020247020178A patent/KR20240108489A/ko active Pending
- 2022-11-18 MX MX2024005996A patent/MX2024005996A/es unknown
- 2022-11-18 CN CN202280076424.9A patent/CN118215657A/zh active Pending
- 2022-11-18 WO PCT/CN2022/132954 patent/WO2023088441A1/zh not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024005996A (es) | 2024-05-30 |
| EP4434979A4 (en) | 2025-10-29 |
| KR20240108489A (ko) | 2024-07-09 |
| CA3237625A1 (en) | 2023-05-25 |
| EP4434979A1 (en) | 2024-09-25 |
| WO2023088441A1 (zh) | 2023-05-25 |
| AU2022389558A1 (en) | 2024-05-23 |
| JP2024542199A (ja) | 2024-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118215657A (zh) | Kif18a抑制剂 | |
| CN118613478A (zh) | Kif18a抑制剂 | |
| CN117279916B (zh) | 含哌嗪结构的parp抑制剂、其制备方法及医药用途 | |
| CN115315427B (zh) | Hpk1抑制剂及其制备方法和用途 | |
| CN113024544B (zh) | 一种含氰基并杂环化合物及其用途 | |
| CN117751116A (zh) | 作为KRas G12D抑制剂的稠环化合物 | |
| CN118434725B (zh) | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 | |
| WO2022105855A1 (en) | Kras g12d inhibitors | |
| CN118076586A (zh) | Kif18a抑制剂 | |
| CN112851663B (zh) | 一种并杂环化合物及其用途 | |
| CN116390728B (zh) | 喹唑啉衍生物及其制备方法和用途 | |
| CN116323617B (zh) | 5,6-二氢吡嗪并[2,3-c]异喹啉化合物 | |
| EP3590944A1 (en) | Azetidine derivative | |
| CN115867542B (zh) | 新型苯并咪唑化合物 | |
| CN120202002A (zh) | 一种用于癌症治疗的药物组合物 | |
| CN118119622A (zh) | 作为shp2抑制剂的稠环化合物 | |
| CN118108704A (zh) | Kif18a抑制剂 | |
| WO2023134608A1 (zh) | 作为hpk1抑制剂的稠环化合物 | |
| CN112513052B (zh) | 氮杂环丁烷衍生物的硼酸酯 | |
| CN118772107B (zh) | Hdac抑制剂及其用途 | |
| CN120693323A (zh) | Kif18a抑制剂 | |
| CN117616026B (zh) | 用作dhodh抑制剂的1,2,4-三唑酮衍生物及其制备方法和用途 | |
| CN118414335A (zh) | 作为Src抑制剂的化合物 | |
| CA3285927A1 (en) | Kif18a inhibitor | |
| CN118480039A (zh) | Kif18a抑制剂及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |